The ectodermal dysplasia receptor activates the nuclear factor-kappaB, JNK, and cell death pathways and binds to ectodysplasin A.

J Biol Chem

Hamon Center for Therapeutic Oncology Research and the Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas 75390-8593, USA.

Published: January 2001

The ectodermal dysplasia receptor (EDAR) is a recently isolated member of the tumor necrosis factor receptor family that has been shown to play a key role in the process of ectodermal differentiation. We present evidence that EDAR is capable of activating the nuclear factor-kappaB, JNK, and caspase-independent cell death pathways and that these activities are impaired in mutants lacking its death domain or those associated with anhidrotic ectodermal dysplasia and the downless phenotype. Although EDAR possesses a death domain, it did not interact with the death domain-containing adaptor proteins TRADD and FADD. EDAR successfully interacted with various TRAF family members; however, a dominant-negative mutant of TRAF2 was incapable of blocking EDAR-induced nuclear factor-kappaB or JNK activation. Collectively, the above results suggest that EDAR utilizes a novel signal transduction pathway. Finally, ectodysplasin A can physically interact with the extracellular domain of EDAR and thus represents its biological ligand.

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M008356200DOI Listing

Publication Analysis

Top Keywords

ectodermal dysplasia
12
nuclear factor-kappab
12
factor-kappab jnk
12
dysplasia receptor
8
cell death
8
death pathways
8
death domain
8
edar
6
death
5
ectodermal
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!